{
    "nct_id": "NCT04033445",
    "official_title": "A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis",
    "inclusion_criteria": "* Documented diagnosis of ulcerative colitis (UC)\n* Moderately to severely active UC, defined by modified Mayo score\n* Demonstrated inadequate response or intolerance to medical therapies specified in the protocol\n* Screening laboratory test results within the parameters specified in the protocol\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, or Crohn's disease or clinical findings suggestive of Crohn's disease\n* UC limited to the rectum only or to less than (<) 20 centimeter (cm) of the colon\n* Presence of a stoma\n* Presence or history of a fistula\n* Receiving prohibited medications and/or treatment",
    "miscellaneous_criteria": ""
}